Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

German firm Oncgnostics said on Thursday that China's National Medical Products Administration approved its DNA methylation-based cervical cancer GynTect assay.

Norwegian life sciences company Age Labs on Wednesday announced a partnership with Bay Area biotech BioAge Labs to harness data from a longitudinal Norwegian health study to develop new diagnostics and drugs.

In the first half of 2022, among the four major business lines of the company, the infectious disease business income reached 3.207 billion CNY, a significant increase of 240.32% over the same period of last year.

Roche said on Wednesday that its Ventana PD-L1 test has received a CE label expansion for its Ventana PD-L1 SP263 test to determine non-small cell lung cancer patients' eligibility for Roche's immune checkpoint inhibitor Tecentriq (atezolizumab).

CorDx said on Wednesday that it has received CE marking for a monkeypox virus antigen test.

Gongdong Medical recently released its 2022 semi-annual report, in which the company achieved operating revenue of CNY 799 million, an increase of 38.70% year-on-year; net profit attributable to shareholders of the listed company was CNY 211 million, an increase of 18.92% year-on-year.

The Wyss Institute and Harvard University said on Tuesday that they have licensed protein detection technology to Spear Bio.

Merck, known as MSD outside the United States and Canada, today announced that the U.S. FDA has granted Fast Track designation for Merck’s investigational anticoagulant therapy MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease.

Recently, the monkeypox virus nucleic acid detection kit (PCR-fluorescent probe method) independently developed by Sansure Biotech has passed the British MHRA certification. This is another authoritative certification obtained after the EU CE.

Pillar Biosciences said Monday that China's National Medical Products Administration has granted commercial approval for its OncoReveal Dx Colon Cancer Assay.